Neurol. praxi. 2022;23(2):174-175 | DOI: 10.36290/neu.2022.024

Hemostyptika u pacientů s rupturou aneuryzmatu
ANO!

MUDr. Jan Vinklárek1, prof. MUDr. Robert Mikulík, Ph.D.1, 2
1 Neurologická klinika Fakultní nemocnice u sv. Anny v Brně a Lékařské fakulty Masarykovy univerzity v Brně
2 Mezinárodní centrum klinického výzkumu v Brně, Cévní program

Published: April 21, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vinklárek J, Mikulík R. Hemostyptika u pacientů s rupturou aneuryzmatu
ANO! Neurol. praxi. 2022;23(2):174-175. doi: 10.36290/neu.2022.024.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Baharoglu MI, Germans MR, Rinkel GJ, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2013;30;2013(8):CD001245. Go to original source... Go to PubMed...
    2. de Gans K, Nieuwkamp DJ, Rinkel GJ, et al. Timing of aneu­rysm surgery in subarachnoid hemorrhage: a systematic review of the literature. Neurosurgery. 2002;50(2):336-340. Go to original source... Go to PubMed...
    3. Germans MR, Post R, Coert BA, et al. Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials. 2013;16;14:143. Go to original source... Go to PubMed...
    4. Hillman J, Fridriksson S, Nilsson O, et al. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg. 2002;97(4):771-778. Go to original source... Go to PubMed...
    5. Kreiter KT, Copeland D, Bernardini GL, et al. Predictors of cognitive dysfunction after subarachnoid hemorrhage. Stroke. 2002;33(1):200-208. Go to original source... Go to PubMed...
    6. Leipzig TJ, Redelman K, Horner TG. Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy. J Neurosurg. 1997;86(2):220-225. Go to original source... Go to PubMed...
    7. Liu-DeRyke X, Rhoney DH. Cerebral vasospasm after aneu­rysmal subarachnoid hemorrhage: an overview of pharmacologic management. Pharmacotherapy. 2006;26(2):182-203. Go to original source... Go to PubMed...
    8. Liu-DeRyke X, Rhoney D. Hemostatic therapy for the treatment of intracranial hemorrhage. Pharmacotherapy. 2008;28(4):485-495. Go to original source... Go to PubMed...
    9. Piriyawat P, Morgenstern LB, Yawn DH, et al. Treatment of acute intracerebral hemorrhage with eaminocaproic acid. Neurocrit Care. 2004;1:47-51. Go to original source... Go to PubMed...
    10. Roos YB, Rinkel GJ, Vermeulen M, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2003;(2):CD001245. Go to original source...
    11. Roos Y, Rinkel G, Vermeulen M, et al. Antifibrinolytic therapy for aneurysmal subarachnoid hemorrhage: a major update of a Cochrane review. Stroke. 2003;34(9):2308-2309. Go to original source... Go to PubMed...
    12. Roos YB, Rinkel GJ, Vermeulen M, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2003;(2):CD001245. Update in: Cochrane Database Syst Rev. 2013;8:CD001245. Go to original source...
    13. Siddiq F, Chaudhry SA, Tummala RP, et al. Factors and outcomes associated with early and delayed aneurysm treat­ment in subarachnoid hemorrhage patients in the United States. Neurosurgery. 2012;71(3):670-677. Go to original source... Go to PubMed...
    14. Starke RM, Kim GH, Fernandez A, et al. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke. 2008;39(9): 2617-2621. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.